Although current treatment standards for breast, ovarian, pancreatic and prostate cancers allow the administration of PARP inhibitors solely on the results of a germline test, ideal patient management would imply the subsequent analysis of tumor tissue aimed to prove the inactivation of the remaining BRCA1/2 allele. This evidence concerns the gene BRCA1 and prostate carcinoma.